Alberto Anel

List of Publications by Year
in descending order

86 papers	8,764 citations	126708 33 h-index	56606 83 g-index
92 all docs	92 docs citations	92 times ranked	18680 citing authors

#	Article	IF	Citations
1	Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma. Cells, 2022, 11, 392.	1.8	7
2	Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). Scientific Reports, 2022, 12, 1341.	1.6	11
3	The metabolism of cells regulates their sensitivity to NK cells depending on p53 status. Scientific Reports, 2022, 12, 3234.	1.6	14
4	Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM). Biomolecules, 2022, 12, 534.	1.8	3
5	Evaluation in a Cytokine Storm Model In Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and) Tj ETQq1 1 0.784314 rgBT /Overloc	1.4	1
6	Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment. Biomedicines, 2022, 10, 1223.	1.4	2
7	In vivo potential of recombinant granulysin against human melanoma. Cancer Treatment and Research Communications, 2021, 27, 100355.	0.7	6
8	Future prospects for mitosis-targeted antitumor therapies. Biochemical Pharmacology, 2021, 190, 114655.	2.0	24
9	Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis. Science Immunology, 2021, 6, eabc2934.	5.6	27
10	Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS). Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 253-274.	2.7	14
11	Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. OncoImmunology, 2021, 10, 1853314.	2.1	24
12	Antibody-Based Immunotoxins for Colorectal Cancer Therapy. Biomedicines, 2021, 9, 1729.	1.4	9
13	Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Scientific Reports, 2020, 10, 19398.	1.6	23
14	Production of a Granulysin-Based, Tn-Targeted Cytolytic Immunotoxin Using Pulsed Electric Field Technology. International Journal of Molecular Sciences, 2020, 21, 6165.	1.8	5
15	Novel Forms of Immunomodulation for Cancer Therapy. Trends in Cancer, 2020, 6, 518-532.	3.8	17
16	Editorial: The Natural Killer Cell Interactome in the Tumor Microenvironment: Basic Concepts and Clinical Application. Frontiers in Immunology, 2020, 11, 872.	2.2	0
17	Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin. OncoImmunology, 2019, 8, 1641392.	2.1	12
18	Mutations in the ND2 Subunit of Mitochondrial Complex I Are Sufficient to Confer Increased Tumorigenic and Metastatic Potential to Cancer Cells. Cancers, 2019, 11, 1027.	1.7	18

#	Article	IF	Citations
19	Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2019, 7, 50.	1.8	139
20	Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy. Cancers, 2019, 11, 444.	1.7	37
21	Role of Exosomes in the Regulation of T-cell Mediated Immune Responses and in Autoimmune Disease. Cells, 2019, 8, 154.	1.8	121
22	Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2019, 7, 306.	1.8	4
23	Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential. Cancers, 2019, 11, 1948.	1.7	14
24	Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma. International Journal of Molecular Sciences, 2018, 19, 1449.	1.8	13
25	Mitochondrial Complex I activity signals antioxidant response through ERK5. Scientific Reports, 2018, 8, 7420.	1.6	38
26	Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors. Theranostics, 2018, 8, 3856-3869.	4.6	48
27	Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. Frontiers in Immunology, 2016, 7, 454.	2.2	26
28	TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells. Nanotechnology, 2016, 27, 185101.	1.3	31
29	High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer. Cancer Letters, 2016, 383, 250-260.	3.2	42
30	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
31	Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein. Oncotarget, 2016, 7, 29287-29305.	0.8	45
32	Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells. Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 197-214.	0.8	8
33	MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. OncoImmunology, 2015, 4, e985924.	2.1	48
34	How Do Cytotoxic Lymphocytes Kill Cancer Cells?. Clinical Cancer Research, 2015, 21, 5047-5056.	3.2	522
35	Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells. Leukemia Research, 2015, 39, 657-666.	0.4	43
36	In vivopotential of recombinant granulysin against human tumors. OncoImmunology, 2015, 4, e1036213.	2.1	15

#	Article	IF	Citations
37	Human NK cells activated by EBV⁺lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. OncoImmunology, 2015, 4, e991613.	2.1	36
38	Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities. Immunotherapy, 2015, 7, 883-882.	1.0	22
39	Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation. Pediatric Research, 2015, 78, 603-608.	1.1	21
40	IFNÎ± signaling through PKC-Î¸ is essential for antitumor NK cell function. OncoImmunology, 2014, 3, e948705.	2.1	10
41	Resumen de la 1.a ReuniÃ³n del Grupo EspaÃ±ol de InmunoTerapia (GEIT). Inmunologia (Barcelona, Spain:) Tj ETQq1 1 0.784314 rgBT	0.1	1
42	Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors. Biochemical Pharmacology, 2014, 87, 410-423.	2.0	29
43	All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. International Journal of Biochemistry and Cell Biology, 2014, 49, 42-52.	1.2	37
44	Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells. Molecular Pharmaceutics, 2013, 10, 893-904.	2.3	70
45	Protein Kinase C-Î¸ (PKC-Î¸) in Natural Killer Cell Function and Anti-Tumor Immunity. Frontiers in Immunology, 2012, 3, 187.	2.2	31
46	Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochemical Pharmacology, 2012, 83, 1475-1483.	2.0	45
47	Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency. Haematologica, 2011, 96, 1195-1203.	1.7	18
48	Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells. Biochemical Pharmacology, 2010, 79, 1746-1758.	2.0	26
49	Liposomeâ€bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 2272-2282.	6.7	84
50	Granzyme B of cytotoxic T cells induces extramitochondrial reactive oxygen species production via caspaseâ€dependent NADPH oxidase activation. Immunology and Cell Biology, 2010, 88, 545-554.	1.0	21
51	Oxidative Phosphorylation Induces De Novo Expression of the MHC Class I in Tumor Cells through the ERK5 Pathway. Journal of Immunology, 2010, 185, 3498-3503.	0.4	58
52	ERK5 Knockdown Generates Mouse Leukemia Cells with Low MHC Class I Levels That Activate NK Cells and Block Tumorigenesis. Journal of Immunology, 2009, 182, 3398-3405.	0.4	28
53	Protein Kinase C-Î¸ Is Required for NK Cell Activation and In Vivo Control of Tumor Progression. Journal of Immunology, 2009, 182, 1972-1981.	0.4	33
54	Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochemical Pharmacology, 2009, 77, 804-812.	2.0	51

#	Article	IF	Citations
55	The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. Microbes and Infection, 2009, 11, 452-459.	1.0	92
56	Impaired anti-leukemic immune response in PKCÎ¸-deficient mice. Molecular Immunology, 2008, 45, 3463-3469.	1.0	21
57	Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. Journal of Leukocyte Biology, 2008, 84, 488-498.	1.5	17
58	The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling. Blood, 2007, 109, 1627-1635.	0.6	25
59	Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation. Immunobiology, 2007, 212, 73-83.	0.8	17
60	Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 loss. Molecular Immunology, 2007, 44, 1446-1453.	1.0	18
61	Mechanism of apoptosis induced by IFN-Î± in human myeloma cells: Role of Jak1 and Bim and potentiation by rapamycin. Cellular Signalling, 2007, 19, 844-854.	1.7	38
62	Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clinical Immunology, 2007, 122, 28-40.	1.4	39
63	Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Experimental Cell Research, 2007, 313, 2378-2388.	1.2	53
64	Apo2L/TRAIL and immune regulation. Frontiers in Bioscience - Landmark, 2007, 12, 2074.	3.0	34
65	A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood, 2006, 108, 1306-1312.	0.6	117
66	Human CD8+ Tâ€„cell blasts are more sensitive than CD4+ Tâ€„cell blasts to regulation by APO2L/TRAIL. European Journal of Immunology, 2005, 35, 1812-1821.	1.6	27
67	Herpesvirus saimiri-transformed CD8+T cells as a tool to study Chediak-Higashi syndrome cytolytic lymphocytes. Journal of Leukocyte Biology, 2005, 77, 661-668.	1.5	7
68	Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c- FLIP, Bim, or Bcl-x isoform expression. Journal of Leukocyte Biology, 2005, 77, 568-578.	1.5	37
69	Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-Î± in human myeloma cells. FEBS Letters, 2005, 579, 6217-6222.	1.3	20
70	Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. Journal of Cell Biology, 2004, 167, 457-468.	2.3	121
71	Differential implication of protein kinase C isoforms in cytotoxic T lymphocyte degranulation and TCR-induced Fas ligand expression. International Immunology, 2003, 15, 1441-1450.	1.8	29
72	Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control. European Journal of Immunology, 2002, 32, 2881-2886.	1.6	112

#	Article	IF	Citations
73	The differential contribution of granzyme A and granzyme B in cytotoxic T lymphocyte-mediated apoptosis is determined by the quality of target cells. European Journal of Immunology, 2002, 32, 1980.	1.6	52
74	Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control. , 2002, 32, 2881.		2
75	The differential contribution of granzyme A and granzyme B in cytotoxic T lymphocyte-mediated apoptosis is determined by the quality of target cells. , 2002, 32, 1980.		1
76	Differential Secretion of Fas Ligand- or APO2 Ligand/TNF-Related Apoptosis-Inducing Ligand-Carrying Microvesicles During Activation-Induced Death of Human T Cells. Journal of Immunology, 2001, 167, 6736-6744.	0.4	240
77	A Role of the Mitochondrial Apoptosis-Inducing Factor in Granulysin-Induced Apoptosis. Journal of Immunology, 2001, 167, 1222-1229.	0.4	103
78	A Distinct Pathway of Cell-Mediated Apoptosis Initiated by Granulysin. Journal of Immunology, 2001, 167, 350-356.	0.4	128
79	CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells. European Journal of Immunology, 2000, 30, 1078-1087.	1.6	28
80	Doxorubicin Treatment Activates a Z-VAD-Sensitive Caspase, Which Causes Î”Î¨m Loss, Caspase-9 Activity, and Apoptosis in Jurkat Cells. Experimental Cell Research, 2000, 258, 223-235.	1.2	127
81	Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. European Journal of Immunology, 1998, 28, 2714-2725.	1.6	179
82	CPP32 inhibition prevents Fas-induced ceramide generation and apoptosis in human cells. FEBS Letters, 1996, 390, 233-237.	1.3	78
83	Role of oxidative damage and IL-1Î²-converting enzyme-like proteases in Fas-based cytotoxicity exerted by effector T cells. International Immunology, 1996, 8, 1173-1183.	1.8	24
84	mtDNA-depleted U937 cells are sensitive to TNF and Fas-mediated cytototxicity. FEBS Letters, 1995, 376, 15-18.	1.3	32
85	Membrane partition of fatty acids and inhibition of T cell function. Biochemistry, 1993, 32, 530-536.	1.2	130
86	Fatty acid metabolism in human lymphocytes. I. Time-course changes in fatty acid composition and membrane fluidity during blastic transformation of peripheral blood lymphocytes. Lipids and Lipid Metabolism, 1990, 1044, 323-331.	2.6	81